阿昔洛韦

DMSO：≥50mg / mL（222.02 mM）

* “≥”表示可溶，但饱和度未知。

[1]. Li Z, et al. Acyclovir treatment of skin lesions results in immune deviation in mice infected cutaneously with herpes simplex virus. Antivir Chem Chemother. 1999 Sep;10(5):251-7.

[2]. Shelley WB, Hashim M, Shelley ED. Acyclovir in the treatment of hand-foot-and-mouth disease. Cutis. 1996 Apr;57(4):232-4.

[3]. Collins P, Oliver NM. Sensitivity monitoring of herpes simplex virus isolates from patients receiving acyclovir. J Antimicrob Chemother. 1986 Oct;18 Suppl B:103-12.

[4]. Meyrick Thomas RH, Dodd HJ, Yeo JM, Oral acyclovir in the suppression of recurrent non-genital herpes simplex virus infection. Br J Dermatol. 1985 Dec;113(6):731-5.

[5]. Tang IY, Maddux MS, Veremis SA, Low-dose oral acyclovir for prevention of herpes simplex virus infection during OKT3 therapy. Transplant Proc. 1989 Feb;21(1 Pt 2):1758-60.

-20℃

避免接触水

1、 摩尔折射率：52.43

2、 摩尔体积（cm3/mol）：127.1

3、 等张比容（90.2K）：384.7

4、 表面张力（dyne/cm）：83.7

5、 极化率（10-24cm3）：20.78

1.疏水参数计算参考值（XlogP）:无

2.氢键供体数量:3